title: Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy?
abstract: BACKGROUND
  Psychiatric disorders are common in HIV patients, and previous work suggests that these patients experience delays in treatment with highly active antiretroviral therapy (HAART). We investigated whether a current psychiatric disorder (1) affected the time to initiation of HAART, (2) predicted the likelihood of being prescribed HAART for at least 6 months, and (3) affected survival in urban AIDS patients.
  
  
  METHODS
  We conducted a retrospective cohort study of AIDS patients with no prior history of HAART who were enrolled and followed at the Johns Hopkins University HIV clinic between January 1996 and January 2002. Patients were stratified based on the presence of a psychiatric disorder. Cox proportional hazards regression models estimated the relative risk of receiving HAART and survival, whereas multivariate logistic regression models estimated the relative odds of remaining on HAART.
  
  
  RESULTS
  During the study period, 549 patients with AIDS and no prior antiretroviral treatment were enrolled in the clinic. Eighteen percent (n = 100) were defined as having a current psychiatric disorder, 39% (n = 215) were defined as having no psychiatric disorder, and 43% (n = 34) were indeterminate. Patients with a psychiatric disorder were 37% more likely to receive HAART (Cox adjusted hazard ratio [95% confidence interval (CI)]: 1.37 [1.01-1.87]), had greater than twice the odds of being prescribed HAART for at least 6 months (adjusted odds ratio [95% CI]: 2.14 [1.24-3.69]), and were 40% more likely to survive (Cox adjusted hazard ratio [95% CI]: 0.61[0.37-0.99]) as compared with those without a psychiatric disorder.
  
  
  CONCLUSIONS
  Patients with psychiatric disorders are receiving HAART and are able to reap the survival benefit by remaining on it.
authors.affiliation: Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21287, USA.
authors.forename: Seth
authors.initials: S
authors.lastname: Himelhoch
authors.forename: Richard D
authors.initials: RD
authors.lastname: Moore
authors.forename: Glenn
authors.initials: G
authors.lastname: Treisman
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Gebo
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015331:Cohort Studies; D015897:Comorbidity; D006801:Humans; D001523:Mental Disorders / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D011619:Psychotropic Drugs; D012189:Retrospective Studies; D012306:Risk; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D011619:Psychotropic Drugs